Clinical trials
Autologous Stem Cell Transplantation clinical trials
Below are recruiting autologous stem cell transplantation clinical trials, each written for real people, not researchers. We’re tracking 214 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03562169RecruitingPhase 3
Ixazomib with your own stem cell transplant for relapsed myeloma
This trial studies whether adding ixazomib (an oral drug) to a transplant using your own stem cells can control relapsed multiple myeloma better. It may help by strengthening anti-myeloma treatment after the transplant, aiming to delay disease progression.
AberdeenAges 18 years+ - NCT04920474Recruiting
Share blood and transplant samples for future research
This study builds a library of transplant and related medical samples to help scientists learn how to improve cell therapies and care for marrow injury. You may be included because you are a donor, receive a transplant or cell therapy, or are treated for marrow toxic injury at participating centers.
New Brighton, MinnesotaAges Any age - NCT05970198Recruiting
Radiation with helical tomotherapy before stem cell transplant
This trial studies a specific type of radiation (helical tomotherapy) in people with multiple myeloma who are planning an autologous stem cell transplant. It may help the study team understand how safe and effective this approach is when used during transplant preparation.
Wuhan, HubeiAges 18–75 - NCT06039735Recruiting
Heart ultrasound study in multiple myeloma treated with RVd
This study looks at how a new heart ultrasound test can measure heart side effects and overall outcomes in people with multiple myeloma who are treated with the RVd drug combination. It may help doctors better understand heart risks during treatment.
Jinan, ShandongAges 18–70 - NCT06218927Recruiting
Stem cell transplant and bladder function in MS
This study looks at whether a stem cell transplant (AHSCT) can improve bladder problems and quality of life in people with multiple sclerosis (MS). It compares people getting this treatment with those on standard MS therapy.
Ostrava, Moravian-Silesian RegionAges 18 years+ - NCT06195800Recruiting
Biomarkers after stem cell transplant for neurological diseases
This trial looks at biomarkers (biological signs in your blood) in people with immune-mediated neurological diseases. It compares those getting a stem cell transplant to those on high-efficacy MS treatments to understand how these therapies work.
Sheffield, EnglandAges 16 years+ - NCT06376214Recruiting
Daratumumab for newly diagnosed light chain amyloidosis
This trial tests the drug daratumumab in people newly diagnosed with light chain amyloidosis that affects the heart, kidney, or liver. The goal is to see if daratumumab can help control the disease. Eligibility depends on your disease stage and overall health.
Nanjing, JiangsuAges 18–75 - NCT06381817RecruitingPhase 3
Stem cell transplant comparison for T-cell leukemia
This study compares two types of stem cell transplants for adults with T-ALL: one using a half-matched donor alone, and one using a half-matched donor plus umbilical cord blood. The goal is to see which approach gives better results with fewer side effects.
Suzhou, JiangsuAges Any age - NCT04201210RecruitingPhase 2
Stem cell transplant study for young people with severe sickle cell
This Phase 2 study tests a type of stem cell transplant that uses donor immune cells that have been specially “tweaked” to help treat sickle cell disease. It may help prevent serious sickle cell complications, but it requires careful matching and screening of organs and pregnancy status.
ViennaAges 2–35 - NCT06567197Recruiting
MS treatment with stem cell transplant in the Netherlands
This trial studies a stem cell transplant treatment for relapsing-remitting multiple sclerosis (RRMS). It aims to see how well this therapy works for people in the Netherlands who have already been approved for it.
AmsterdamAges 18–65 - NCT06608342RecruitingPhase 2
Stem cell transplant plus CAR-T for high-risk leukemia
This trial tests a combination of your own stem cell transplant and a personalized CAR-T cell therapy called CD19-CAR-T. It is for adults with high-risk acute B-lymphoblastic leukemia whose cancer is in remission after initial chemotherapy, and who are able to receive both treatments safely.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT05889585Recruiting
Life after germ cell cancer treatment side effects study
This study looks at long-term health problems and quality of life in people who survived germ cell tumors after strong chemotherapy with a stem cell transplant or other standard treatments. It may help doctors understand which late side effects are most common and how to better support survivors.
VillejuifAges 18 years+ - NCT06589089RecruitingPhase 2
Stem cell boost after CAR-T for lymphoma
This trial tests giving patients their own stored stem cells after CAR-T therapy to help recover low blood counts. It is for people with B-cell non-Hodgkin lymphoma whose blood counts are still low after CAR-T and who have a stable response to treatment.
ShanghaiAges 18 years+ - NCT07680933RecruitingPhase 2
Orelabrutinib plus chemo for newly diagnosed DLBCL
This trial tests if adding orelabrutinib (a targeted pill) to standard chemotherapy, with or without a stem cell transplant, works better for people with a new diagnosis of diffuse large B-cell lymphoma. It may help patients who have a higher risk of the lymphoma coming back.
Xuzhou, JiangsuAges 18–80 - NCT07678229RecruitingPhase 3
Immunotherapy vs Chemotherapy for Advanced NK/T-cell Lymphoma
This trial compares an immunotherapy approach to standard chemotherapy as a first step before stem cell transplant for patients with advanced NK/T-cell lymphoma. It aims to see which treatment helps patients better before their own stem cells are transplanted.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06608732RecruitingPhase 2
CAR-T therapy plus stem cell transplant for B-cell ALL with MRD
This trial tests a combination of a CAR-T cell therapy (Inaticabtagene Autoleucel) followed by your own stem cells being transplanted back into you. It is for teenagers and adults who have B-cell acute lymphoblastic leukemia (ALL) that is in first complete remission but still has tiny amounts of cancer cells (called MRD) that can be detected by sensitive tests.
Tianjin, Tianjin MunicipalityAges 16–70 - NCT07662018Recruiting
Study of stem cell transplant after chemo for children with germ cell tumors
This study looks at how well a stem cell transplant works after a specific combination of chemotherapy drugs (gemcitabine, docetaxel, melphalan, and carboplatin) in children and young adults up to age 21 whose germ cell tumors have come back or not responded to treatment. It may help doctors understand who benefits most from this approach.
Houston, TexasAges 21 years+ - NCT07635693Recruiting
ATLG Levels During Stem Cell Transplant for Multiple Sclerosis
This study measures how a specific immune-suppressing medication (ATLG) works in patients with multiple sclerosis who are undergoing autologous stem cell transplantation—a procedure where your own blood stem cells are removed, treated, and returned to help reset your immune system.
Milan, ItalyAges 18 years+ - NCT06588413RecruitingPhase 3
Comparing two doses of olanzapine for nausea after stem cell transplant
This trial tests whether a lower dose of olanzapine (2.5 mg) works as well as the usual dose (5 mg) for preventing nausea and vomiting caused by high-dose melphalan chemotherapy. It is for people receiving their own stem cell transplant.
Augusta, GeorgiaAges 18 years+ - NCT05745532RecruitingEarly Phase 1
Autologous stem cell treatment to improve beta thalassemia major
This early-phase trial tests a new way to restore working blood-making cells using your own stem cells for people with transfusion-dependent beta thalassemia major. The goal is to improve safety and blood results, and possibly reduce problems from the disease.
Shenzhen, GuangdongAges 8–16 - NCT07605416RecruitingPhase 2
Testing New Drug Combination for Plasma Cell Leukemia
This study tests a new combination of medicines to treat plasma cell leukemia, a rare blood cancer. The trial aims to help patients newly diagnosed with this condition by using drugs that work against cancer cells in different ways.
New Haven, ConnecticutAges 18–80 - NCT07607197RecruitingPhase 1/Phase 2
Immune Reset to Help Highly Sensitized Kidney Transplant Patients
This study tests whether a special immune-resetting treatment can help patients who have developed too many antibodies against donor kidneys get access to a compatible kidney transplant. The treatment uses chemotherapy and stem cell transplantation to 'reset' your immune system so it stops rejecting potential donor kidneys.
Barcelona, CataloniaAges 18–60 - NCT07582172RecruitingPhase 2
Stem Cell Transplant for Hard-to-Treat Blood Cancers in Older Adults
This trial tests a new combination of radiation and chemotherapy to prepare your body for a stem cell transplant from a matched donor. It's designed for older patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that hasn't responded well to standard treatments.
Duarte, CaliforniaAges 18 years+ - NCT05665140RecruitingPhase 2/Phase 3
Newly diagnosed myeloma study using blood-marker risk groups
This Phase 2/3 trial tests whether matching treatment choices to a patient’s myeloma risk pattern (using blood and scan results) improves outcomes. It is for people with newly diagnosed, untreated, symptomatic multiple myeloma who may also receive transplant-related treatment.
BerlinAges 18–70
Hear when a new Autologous Stem Cell Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for autologous stem cell transplantation?
- Yes. Clin2 currently lists 214 recruiting autologous stem cell transplantation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a autologous stem cell transplantation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a autologous stem cell transplantation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Autologous Hematopoietic Stem Cell Transplantation
- Hematopoietic Stem Cell Transplantation
- Allogeneic Hematopoietic Stem Cell Transplantation
- Stem Cell Transplantation
- Hematopoetic Stem Cell Transplantation
- Allogeneic Stem Cell Transplantation
- Allogeneic Hematopoietic Stem Cell Transplantation Recipient
- Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.